Amicus Therapeutics (NASDAQ:FOLD – Get Free Report) and Immuneering (NASDAQ:IMRX – Get Free Report) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, earnings, dividends, institutional ownership, profitability and analyst recommendations.
Valuation & Earnings
This table compares Amicus Therapeutics and Immuneering”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Amicus Therapeutics | $528.29 million | 8.49 | -$56.11 million | ($0.04) | -357.25 |
| Immuneering | N/A | N/A | -$61.04 million | ($1.78) | -2.93 |
Profitability
This table compares Amicus Therapeutics and Immuneering’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Amicus Therapeutics | -2.35% | 6.95% | 1.75% |
| Immuneering | N/A | -73.49% | -65.01% |
Risk & Volatility
Amicus Therapeutics has a beta of 0.42, indicating that its share price is 58% less volatile than the S&P 500. Comparatively, Immuneering has a beta of 0.48, indicating that its share price is 52% less volatile than the S&P 500.
Analyst Ratings
This is a summary of current ratings and price targets for Amicus Therapeutics and Immuneering, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Amicus Therapeutics | 1 | 8 | 4 | 1 | 2.36 |
| Immuneering | 1 | 0 | 5 | 1 | 2.86 |
Amicus Therapeutics presently has a consensus price target of $15.55, indicating a potential upside of 8.82%. Immuneering has a consensus price target of $16.50, indicating a potential upside of 216.09%. Given Immuneering’s stronger consensus rating and higher probable upside, analysts clearly believe Immuneering is more favorable than Amicus Therapeutics.
Insider & Institutional Ownership
67.7% of Immuneering shares are owned by institutional investors. 2.2% of Amicus Therapeutics shares are owned by insiders. Comparatively, 22.9% of Immuneering shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Summary
Immuneering beats Amicus Therapeutics on 8 of the 13 factors compared between the two stocks.
About Amicus Therapeutics
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
About Immuneering
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
